-
Mashup Score: 0Journal Review of New Medications, Recent Guidelines in Dermatology - 30 minute(s) ago
In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.
Source: www.hcplive.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Stratifying BMI With Waist Circumference Improved Mortality Risk Prediction in Postmenopausal Women - 30 minute(s) ago
As per a prospective cohort study, waist circumference along with BMI modestly improves the prediction of which postmenopausal women are at a higher risk for premature death.
Source: www.medscape.comCategories: General Medicine NewsTweet-
By using waist circumference along with BMI, modest gains were made in predicting which postmenopausal women were at a higher risk for premature death, a prospective cohort study has found. https://t.co/ZLFgN9ADSM https://t.co/zC8QgRSD79
-
-
Mashup Score: 0
Two of Cytiva’s top executives offer updates on the company’s $1.6 billion in expansion projects worldwide, all to meet growing market demand for its services from developers and manufacturers of advanced therapeutics.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
"In-Region, For Region": Cytiva Builds Out $1.6B in Global Expansion Projects Two of @Cytiva’s top executives offer updates on the company's $1.6 billion in expansion projects worldwide, all to meet growing market demand #therapeutics #biomanufacturing https://t.co/pWexJwQ62e
-
-
Mashup Score: 0
Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
New data from 7 phase 3 trials show ruxolitinib cream is safe long-term for kids & adults with #AtopicDermatitis and #vitiligo with low rates of serious adverse events. #dermatology #SDPA2025 https://t.co/y8uFwcoeD1
-
-
Mashup Score: 0Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML - 30 minute(s) ago
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Findings from a phase 3 trial demonstrated that dasatinib plus induction and consolidation therapy, followed by 12 months of maintenance, did not yield EFS or OS improvements vs standard-of-care therapy for patients with core-binding factor #AML. https://t.co/bN6BU85UHY
-
-
Mashup Score: 0FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer - 30 minute(s) ago
FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer @ASCO #ASCO25 #oncology https://t.co/btFMI9rnVa
-
-
Mashup Score: 0
“The 62nd ERA Congress: VISIONARY Trials, VALIANT Advances, and Beyond Nephrology” published on 08 Jul 2025 by American Society of Nephrology.
Source: www.kidneynews.orgCategories: General Medicine News, NephrologyTweet-
ASN Kidney News July 2025 The 62nd ERA Congress: VISIONARY Trials, VALIANT Advances, and Beyond Nephrology @wisit661 Andrea Angioi @NephroSeeker https://t.co/eIF2Cupmpu @asnpublications @ERAkidney
-
-
Mashup Score: 9Modifications of microbiome-derived cell-free RNA in plasma discriminates colorectal cancer samples - 34 minute(s) ago
Nature Biotechnology – Colorectal cancer is discriminated by measuring cell-free RNA methylation in plasma.
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet-
A new way to get very early detection of colon cancer using cell-free RNA (instead of DNA) @NatureBiotech https://t.co/S5XErpdPTB
-
-
Mashup Score: 0A breakthrough in a Harvard lab led to a new cancer drug. Could it save a man with six months to live? - The Boston Globe - 36 minute(s) ago
The hunt for a medical breakthrough has been caught up in the Trump administration’s political assault on the university.
Source: www.bostonglobe.comCategories: General Medicine NewsTweet-
He had six months to live. Then came an experimental cancer treatment launched by Harvard researchers. Before her federal funding was cut, Dr. Arlene Sharpe and colleagues paved the way for immunotherapy treatments. https://t.co/8558FKfHL1
-
-
Mashup Score: 1OpenAI and Microsoft Bankroll New A.I. Training for Teachers - 37 minute(s) ago
The American Federation of Teachers said it would use the $23 million, including $500,000 from the A.I. start-up Anthropic, to create a national training center.
Source: www.nytimes.comCategories: General Medicine NewsTweet-
OpenAI and Microsoft Bankroll New A.I. Training for Teachers The American Federation of Teachers said it would use the $23 million, including $500,000 from the A.I. start-up Anthropic, to create a national training center. https://t.co/EQoGp4f4a0 https://t.co/K6L0wvMDqb
-
The #SDPA2025 featured a session titled ‘Journal Review’ wherein a variety of clinically relevant articles from the past year regarding recent medications, changes in practice, and other key information in dermatology were highlighted. View here: https://t.co/aetQx85rmv https://t.co/zji6oe7wcI